Qureshi Adnan I, Malik Ahmed A, Saeed Omar, Adil Malik M, Rodriguez Gustavo J, Suri M Fareed K
Zeenat Qureshi Stroke Institute, St. Cloud, Minn., USA.
Cerebrovasc Dis. 2015;39(5-6):262-8. doi: 10.1159/000375154. Epub 2015 Apr 8.
Subclinical cancer can manifest as a thromboembolic event and may be detected at a later interval in ischemic stroke survivors. We determined the rate of incident cancer and effect on cardiovascular endpoints in a large cohort of ischemic stroke survivors.
An analysis of 3,680 adults with nondisabling cerebral infarction who were followed for two years within the randomized, double-blinded VISP trial was performed. The primary intervention was best medical/surgical management plus a daily supplementation of vitamin B6, vitamin B12, and folic acid. We calculated age-adjusted rates of incidence of cancer among ischemic stroke survivors and standardized incidence ratios (SIR) with 95% confidence intervals (CI) based on comparison with age-adjusted rates in the general population. The significant variables from univariate analysis were entered in a Cox Proportional Hazards analysis to identify the association between various baseline factors and incident cancer after adjusting age, gender, and race/ethnicity. A logistic regression analysis evaluated the association between incident cancer and various endpoints including stroke, coronary heart disease, myocardial infarction, and death after adjusting age, gender, and race/ethnicity.
A total of 3,247 patients (mean age ± SD of 66 ± 11; 2,013 were men) were cancer free at the time of enrollment. The incidence of new cancer was 0.15, 0.80, 1.2, and 2.0 per 100 patients at 1 month, 6 months, 1 year, and 2 years, respectively. The age-adjusted annual rate of cancer in patients with ischemic stroke was higher than in persons in the general population at 1 year (581.8/100,000 persons vs. 486.5/100,000 persons, SIR 1.2, 95% CI 1.16-1.24) and 2 years (1,301.7/100,000 vs. 911.5/100,000, SIR 1.4, 95% CI 1.2-1.6) after recruitment. There was a higher risk for death (odds ratio (OR) 3.1, 95% CI 1.8-5.4), and composite endpoint of stroke, coronary heart disease, and/or death (OR 1.4, 95% CI 1.0-2.2) among participants who developed incident cancer compared with those who were cancer free after adjusting for potential confounders.
The annual rate of age-adjusted cancer incidence was higher among ischemic stroke patients compared with those in the general population. The odds of mortality were three folds higher among stroke survivors who developed incident cancer.
亚临床癌症可表现为血栓栓塞事件,且可能在缺血性卒中幸存者随访后期被发现。我们在一大群缺血性卒中幸存者中确定了癌症发病率及其对心血管终点事件的影响。
对3680例非致残性脑梗死成人进行分析,这些患者在随机双盲的VISP试验中接受了两年的随访。主要干预措施为最佳药物/手术治疗加每日补充维生素B6、维生素B12和叶酸。我们计算了缺血性卒中幸存者中年龄调整后的癌症发病率,并根据与一般人群年龄调整率的比较得出标准化发病率(SIR)及95%置信区间(CI)。单因素分析中的显著变量被纳入Cox比例风险分析,以确定在调整年龄、性别和种族/民族后各种基线因素与新发癌症之间的关联。逻辑回归分析评估了在调整年龄、性别和种族/民族后新发癌症与包括卒中、冠心病、心肌梗死和死亡在内的各种终点事件之间的关联。
共有3247例患者(平均年龄±标准差为66±11岁;2013例为男性)在入组时无癌症。新发癌症的发病率在1个月、6个月、1年和2年时分别为每100例患者0.15、0.80、1.2和2.0例。缺血性卒中患者年龄调整后的年癌症发病率在入组后1年(581.8/100,000人 vs. 486.5/100,000人,SIR 1.2,95%CI 1.16 - 1.24)和2年(1301.7/100,000 vs. 911.5/100,000,SIR 1.4,95%CI 1.2 - 1.6)高于一般人群。在调整潜在混杂因素后,发生新发癌症的参与者死亡风险更高(比值比(OR)3.1,95%CI 1.8 - 5.4),以及卒中、冠心病和/或死亡的复合终点事件风险更高(OR 1.4,95%CI 1.0 - 2.2)。
与一般人群相比,缺血性卒中患者年龄调整后的年癌症发病率更高。发生新发癌症的卒中幸存者死亡几率高出三倍。